Developer docs
API playgroundTry for free, no card

Search company profiles

Basilea Pharmaceutica

Full company profile

uuid0000h3u

Namestring
Basilea Pharmaceutica
Legal namestring
Basilea Pharmaceutica Ltd
Websiteurl
basilea.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

Basilea Pharmaceutica Ltd is a Swiss commercial-stage biopharmaceutical company founded in 2000 and headquartered in Allschwil, Switzerland, listed on the SIX Swiss Exchange under ticker BSLN. The company focuses on discovering, developing, and commercializing innovative drugs for patients with severe and life-threatening bacterial and fungal infections, primarily in hospital settings. Its commercial portfolio comprises two hospital brands: Cresemba (isavuconazole), an antifungal for invasive fungal infections marketed globally via a license partnership with Pfizer in more than 75 countries and generating CHF 111.6 million in royalty income in 2025, and Zevtera (ceftobiprole), an antibacterial directly launched in the US market in 2025.

The company's pipeline targets antimicrobial resistance through multiple novel mechanisms of action: fosmanogepix (Gwt1 inhibitor, Phase 3) and BAL2062 for invasive fungal infections, ceftibuten-ledaborbactam (beta-lactam/beta-lactamase inhibitor combination, Phase 3-ready with FDA QIDP and Fast Track designations, in-licensed from Venatorx) for complicated urinary tract infections, and BAL2420 (LptA inhibitor targeting Gram-negative bacteria, Phase 1 initiated March 2026). Basilea's revenue model is hybrid: licensing royalties and milestone payments from Pfizer on Cresemba global sales, plus direct US sales of Zevtera and non-dilutive funding from BARDA (up to USD 268 million for antifungals, up to USD 147 million for the cUTI program) and CARB-X for pipeline advancement.

In FY2025, Basilea reported revenue of CHF 232.4 million (+11.4% YoY), operating profit of CHF 51.5 million (22% EBIT margin), and a net cash position of CHF 86.9 million (tripled YoY). R&D investment rose 37.4% to CHF 106 million. The company has guided FY2026 revenue to approximately CHF 255-257 million (~10% growth) with approximately 20% EBIT growth, targeting two new product launches by 2030. Strategic partnerships include Pfizer (commercial), BARDA and CARB-X (non-dilutive funding), INCATE (industry consortium), Phare Bio (AI-driven discovery), and Prokaryotics (antifungal co-development).

Short descriptiontext

Basilea Pharmaceutica is a Swiss commercial-stage biopharmaceutical company developing and commercializing anti-infective drugs for severe bacterial and fungal infections, serving hospital-based infectious disease specialists globally through marketed brands Cresemba and Zevtera and a pipeline targeting antimicrobial resistance.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersAllschwil, Switzerland
HQ citystring
Allschwil
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
anti-infective pharmaceuticals, antifungal drugs, antibacterial drugs, hospital brand pharmaceuticals, antimicrobial resistance
Industry1 code
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Anti-Infective Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Product Royalties (Cresemba)
TypeLicensing Royalties
Description

Basilea earns royalty income from global sales of Cresemba (isavuconazole), its antifungal drug marketed in over 75 countries. Cresemba royalties were CHF 111.6 million in 2025, representing 15% growth year-over-year, driven by USD 693 million in in-market sales globally. Cresemba achieved its ten-year market anniversary in 2025.

globenewswire.com
2Milestone Payments
TypeLicensing Royalties
Description

Basilea receives milestone payments from license partners upon achievement of sales thresholds and development milestones. A USD 30 million milestone was triggered in November 2025 from Pfizer for strong Cresemba sales performance in Europe exceeding sales thresholds.

globenewswire.com
3Product Sales (Zevtera)
TypeLicensing Royalties
Description

Basilea launched Zevtera in the US market (mid-2025) as an antibacterial product. Combined Cresemba and Zevtera-related revenue guidance for 2026 is approximately CHF 200 million.

markets.ft.com
4Non-dilutive Government Funding
TypeManaged Services
Description

Basilea receives non-dilutive funding from BARDA (up to USD 268 million over 12 years for antifungals, up to USD 147 million for cUTI antibiotic program) and CARB-X (multiple tranches including USD 6 million additional funding in 2026 for BAL2420 Phase 1). Funding supports clinical development without diluting equity.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Cresemba
Description

Antifungal drug (isavuconazole) for the treatment of invasive fungal infections. Marketed in over 75 countries globally with USD 693 million in-market sales and 27% year-over-year growth as of 2025.

basilea.com
+1 more record
Core offering1 text field

Basilea Pharmaceutica is a commercial-stage biopharmaceutical company that develops and commercializes innovative drugs to address severe bacterial and fungal infections. It has two marketed hospital brands — Cresemba (isavuconazole) for invasive fungal infections and Zevtera (ceftobiprole) for bacterial infections — and a clinical pipeline of novel antifungals and antibiotics targeting antimicrobial resistance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Cresemba generated USD 693 million in in-market sales with 27% year-over-year growth in 2025
+4 more records
Product overview1 text field

Basilea Pharmaceutica is a commercial-stage biopharmaceutical company with two marketed hospital brands: Cresemba (antifungal for invasive fungal infections) and Zevtera (antibiotic for bacterial infections). The portfolio is supported by a pipeline of anti-infective candidates in clinical development including antifungals fosmanogepix and BAL2062, and antibiotics ceftibuten-ledaborbactam (oral, Phase 3-ready) and BAL2420 (LptA inhibitor, Phase 1). The company operates a focused anti-infectives strategy combining commercialized products generating royalty revenue with advancing novel pipeline candidates through clinical development.

Product and service6 records
1Cresemba
CategoryMarketed Antifungal
Description

Antifungal drug (isavuconazole) for the treatment of invasive fungal infections. Commercialized in over 75 countries with strong royalty income contribution; global in-market sales of USD 693 million in 2025 with 27% year-over-year growth.

2Zevtera
CategoryMarketed Antibiotic
Description

Intravenous antibiotic (ceftobiprole) for the treatment of bacterial infections. Successfully launched in the US market in 2025, representing Basilea's first company-initiated commercial launch.

3Fosmanogepix
CategoryPipeline Antifungal
Description

Novel antifungal candidate in Phase 3 clinical development for invasive fungal infections, primarily affecting immunocompromised patients. Targets Candida, Aspergillus and rare molds. Supported by BARDA funding.

4BAL2062
CategoryPipeline Antifungal
Description

Antifungal drug candidate in clinical development for invasive fungal infections, supported by BARDA under the multi-year OTA.

5Ceftibuten-Ledaborbactam (Etzadroxil)
CategoryPipeline Antibiotic
Description

Novel oral antibiotic (beta-lactam/beta-lactamase inhibitor combination) for treating complicated urinary tract infections (cUTIs). In-licensed from Venatorx Pharmaceuticals, Phase 3-ready with FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations.

6BAL2420 (LptA Inhibitor)
CategoryPipeline Antibiotic
Description

Novel antibiotic targeting LptA (lipopolysaccharide transport protein A), part of the lipopolysaccharide transport bridge essential in Gram-negative bacteria. Has shown potent and rapid bactericidal activity against Enterobacteriaceae including E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin. First-in-human Phase 1 study started March 2026.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Basilea joined INCATE as an industry partner, one of four alongside Roche, Shionogi, and MSD. This marks INCATE's first expansion into antifungals. The partnership leverages Basilea's preclinical, clinical, and commercial expertise to transform early-stage antibacterial and antifungal concepts into assets through industry partnerships.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

Collaboration to jointly develop a first-in-class broad-spectrum antifungal for severe invasive infections caused by Candida, Aspergillus, and rare molds. Basilea makes an undisclosed upfront payment and near-term milestones to Prokaryotics, with potential development, regulatory, and commercial milestone payments up to USD 48.5 million plus tiered royalties. Basilea assumes responsibility for clinical development and global commercialization under an exclusive global license.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-11
Description

Partnership to develop a novel antibiotic using AI-driven molecule design. Combines Basilea's anti-infectives drug development expertise with Phare Bio's AI capabilities for antimicrobial resistance. Phare Bio eligible for success-based payments.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Pfizer is the global license partner for Cresemba (isavuconazole), Basilea's antifungal drug. Pfizer markets Cresemba in over 75 countries. Strong sales performance in Europe triggered a USD 30 million milestone payment to Basilea in November 2025, with global Cresemba sales of USD 652 million for the 12 months ending June 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Basilea in-licensed the Phase 3-ready antibiotic ceftibuten-ledaborbactam from Venatorx Pharmaceuticals. This in-licensing added a late-stage oral antibiotic candidate targeting complicated urinary tract infections, subsequently supported by BARDA funding of up to USD 147 million.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Pfizer is Basilea's global license partner for Cresemba and the global leader in anti-infectives (including its own antifungal and antibacterial portfolios). Comparable as both a commercial channel for Cresemba and as a broad incumbent whose anti-infective franchise overlaps with Basilea's hospital focus.

TypeDirect peer
Description

F2G is a direct antifungal peer developing olorofim, a novel mechanism antifungal for invasive fungal infections including resistant Aspergillus. Highly comparable niche competitor pursuing the same immunocompromised-patient hospital antifungal market that Basilea's Cresemba and fosmanogepix target.

TypeDirect peer
Description

Scynexis developed and commercialized ibrexafungerp (Brexafemme), a novel glucan synthase inhibitor antifungal. Comparable as a small-cap antifungal innovator focused on invasive fungal infections, with a similar commercial-stage + pipeline profile to Basilea's antifungal franchise.

TypeEmerging player
Description

Cidara is developing rezafungin, a next-generation echinocandin antifungal for invasive candidiasis, overlapping with Basilea's Cresemba and fosmanogepix in hospital antifungal treatment of serious fungal infections.

TypeBroad incumbent
Description

Melinta is a commercial-stage anti-infectives company with a hospital antibiotic portfolio (Baxdela, Vabomere, Orbactiv, Minocin). Comparable as a broader anti-infectives specialty player addressing similar hospital bacterial infection indications as Basilea's Zevtera and ceftibuten-ledaborbactam.

TypeDirect peer
Description

Iterum is developing oral sulopenem for complicated urinary tract infections, directly comparable to Basilea's ceftibuten-ledaborbactam. Both are late-stage oral antibiotics targeting drug-resistant cUTIs, a relatively narrow competitive set with similar FDA regulatory pathways.

TypeDirect peer
Description

Venatorx originated ceftibuten-ledaborbactam, which Basilea in-licensed. As a private anti-infectives developer focused on beta-lactamase inhibitor combinations and Gram-negative resistance, Venatorx is a direct comparable in the hospital antibacterial space.

TypeEmerging player
Description

Entasis, a subsidiary of Innoviva, developed Xacduro for Acinetobacter infections and operates as a focused anti-infectives developer with novel-mechanism antibiotics. Comparable as a niche anti-infectives specialist advancing Gram-negative therapies similar to Basilea's BAL2420 and fosmanogepix programs.

9Nabriva Therapeutics
TypeEmerging player
Description

Nabriva developed lefamulin (Xenleta), a novel pleuromutilin antibiotic for community-acquired bacterial pneumonia. Comparable as a small-cap anti-infectives company with a marketed hospital antibiotic and a similar commercial-stage + specialty focus.

TypeOthers
Description

Tetraphase developed eravacycline (Xerava), a novel tetracycline antibiotic for complicated intra-abdominal infections, and was acquired by La Jolla Pharmaceutical. Comparable as a historical reference point for small-cap novel antibiotic developers targeting serious hospital infections, though it no longer operates as an independent entity.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Basilea Pharmaceutica

Anti-Infective Pharmaceuticalsbasilea.com

Basilea Pharmaceutica is a Swiss commercial-stage biopharmaceutical company developing and commercializing anti-infective drugs for severe bacterial and fungal infections, serving hospital-based infectious disease specialists globally through marketed brands Cresemba and Zevtera and a pipeline targeting antimicrobial resistance.

What Basilea Pharmaceutica does

Basilea Pharmaceutica Ltd is a Swiss commercial-stage biopharmaceutical company founded in 2000 and headquartered in Allschwil, Switzerland, listed on the SIX Swiss Exchange under ticker BSLN. The company focuses on discovering, developing, and commercializing innovative drugs for patients with severe and life-threatening bacterial and fungal infections, primarily in hospital settings. Its commercial portfolio comprises two hospital brands: Cresemba (isavuconazole), an antifungal for invasive fungal infections marketed globally via a license partnership with Pfizer in more than 75 countries and generating CHF 111.6 million in royalty income in 2025, and Zevtera (ceftobiprole), an antibacterial directly launched in the US market in 2025.

The company's pipeline targets antimicrobial resistance through multiple novel mechanisms of action: fosmanogepix (Gwt1 inhibitor, Phase 3) and BAL2062 for invasive fungal infections, ceftibuten-ledaborbactam (beta-lactam/beta-lactamase inhibitor combination, Phase 3-ready with FDA QIDP and Fast Track designations, in-licensed from Venatorx) for complicated urinary tract infections, and BAL2420 (LptA inhibitor targeting Gram-negative bacteria, Phase 1 initiated March 2026). Basilea's revenue model is hybrid: licensing royalties and milestone payments from Pfizer on Cresemba global sales, plus direct US sales of Zevtera and non-dilutive funding from BARDA (up to USD 268 million for antifungals, up to USD 147 million for the cUTI program) and CARB-X for pipeline advancement.

In FY2025, Basilea reported revenue of CHF 232.4 million (+11.4% YoY), operating profit of CHF 51.5 million (22% EBIT margin), and a net cash position of CHF 86.9 million (tripled YoY). R&D investment rose 37.4% to CHF 106 million. The company has guided FY2026 revenue to approximately CHF 255-257 million (~10% growth) with approximately 20% EBIT growth, targeting two new product launches by 2030. Strategic partnerships include Pfizer (commercial), BARDA and CARB-X (non-dilutive funding), INCATE (industry consortium), Phare Bio (AI-driven discovery), and Prokaryotics (antifungal co-development).

Basilea Pharmaceutica firmographics

Firmographics
Name
Basilea Pharmaceutica
Legal name
Basilea Pharmaceutica Ltd
Website
https://basilea.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
251–500 employees
Short description
Basilea Pharmaceutica is a Swiss commercial-stage biopharmaceutical company developing and commercializing anti-infective drugs for severe bacterial and fungal infections, serving hospital-based infectious disease specialists globally through marketed brands Cresemba and Zevtera and a pipeline targeting antimicrobial resistance.
Ownership category
akta.pro rank

Basilea Pharmaceutica industry classification

Industry
Product category
Anti-Infective Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Anti-infective pharmaceuticals
  • Antifungal drugs
  • Antibacterial drugs
  • Hospital brand pharmaceuticals
  • Antimicrobial resistance

Where Basilea Pharmaceutica is headquartered

Location

Headquarters

HQ city
Allschwil
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Basilea Pharmaceutica business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Product Royalties (Cresemba): Basilea earns royalty income from global sales of Cresemba (isavuconazole), its antifungal drug marketed in over 75 countries. Cresemba royalties were CHF 111.6 million in 2025, representing 15% growth year-over-year, driven by USD 693 million in in-market sales globally. Cresemba achieved its ten-year market anniversary in 2025.
  2. Milestone Payments: Basilea receives milestone payments from license partners upon achievement of sales thresholds and development milestones. A USD 30 million milestone was triggered in November 2025 from Pfizer for strong Cresemba sales performance in Europe exceeding sales thresholds.
  3. Product Sales (Zevtera): Basilea launched Zevtera in the US market (mid-2025) as an antibacterial product. Combined Cresemba and Zevtera-related revenue guidance for 2026 is approximately CHF 200 million.
  4. Non-dilutive Government Funding: Basilea receives non-dilutive funding from BARDA (up to USD 268 million over 12 years for antifungals, up to USD 147 million for cUTI antibiotic program) and CARB-X (multiple tranches including USD 6 million additional funding in 2026 for BAL2420 Phase 1). Funding supports clinical development without diluting equity.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Basilea Pharmaceutica product offering

Product offering

Core offering

Basilea Pharmaceutica is a commercial-stage biopharmaceutical company that develops and commercializes innovative drugs to address severe bacterial and fungal infections. It has two marketed hospital brands — Cresemba (isavuconazole) for invasive fungal infections and Zevtera (ceftobiprole) for bacterial infections — and a clinical pipeline of novel antifungals and antibiotics targeting antimicrobial resistance.

Product overview

Basilea Pharmaceutica is a commercial-stage biopharmaceutical company with two marketed hospital brands: Cresemba (antifungal for invasive fungal infections) and Zevtera (antibiotic for bacterial infections). The portfolio is supported by a pipeline of anti-infective candidates in clinical development including antifungals fosmanogepix and BAL2062, and antibiotics ceftibuten-ledaborbactam (oral, Phase 3-ready) and BAL2420 (LptA inhibitor, Phase 1). The company operates a focused anti-infectives strategy combining commercialized products generating royalty revenue with advancing novel pipeline candidates through clinical development.

Differentiator

Problem solved

Functional benefit

Brands

  • Cresemba: Antifungal drug (isavuconazole) for the treatment of invasive fungal infections. Marketed in over 75 countries globally with USD 693 million in-market sales and 27% year-over-year growth as of 2025.
  • Zevtera

Products and services

  • Cresemba Antifungal drug (isavuconazole) for the treatment of invasive fungal infections. Commercialized in over 75 countries with strong royalty income contribution; global in-market sales of USD 693 million in 2025 with 27% year-over-year growth.
  • Zevtera Intravenous antibiotic (ceftobiprole) for the treatment of bacterial infections. Successfully launched in the US market in 2025, representing Basilea's first company-initiated commercial launch.
  • Fosmanogepix Novel antifungal candidate in Phase 3 clinical development for invasive fungal infections, primarily affecting immunocompromised patients. Targets Candida, Aspergillus and rare molds. Supported by BARDA funding.
  • BAL2062 Antifungal drug candidate in clinical development for invasive fungal infections, supported by BARDA under the multi-year OTA.
  • Ceftibuten-Ledaborbactam (Etzadroxil) Novel oral antibiotic (beta-lactam/beta-lactamase inhibitor combination) for treating complicated urinary tract infections (cUTIs). In-licensed from Venatorx Pharmaceuticals, Phase 3-ready with FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations.
  • BAL2420 (LptA Inhibitor) Novel antibiotic targeting LptA (lipopolysaccharide transport protein A), part of the lipopolysaccharide transport bridge essential in Gram-negative bacteria. Has shown potent and rapid bactericidal activity against Enterobacteriaceae including E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin. First-in-human Phase 1 study started March 2026.

Quantifiable outcome

  • Cresemba generated USD 693 million in in-market sales with 27% year-over-year growth in 2025
  • +4 more outcomes

Companies that use Basilea Pharmaceutica

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Basilea Pharmaceutica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Basilea Pharmaceutica partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • INCATE (Incubator for Antibacterial Therapies in Europe)minorStrategic or Co-development Partner · 13 January 2026Basilea joined INCATE as an industry partner, one of four alongside Roche, Shionogi, and MSD. This marks INCATE's first expansion into antifungals. The partnership leverages Basilea's preclinical, clinical, and commercial expertise to transform early-stage antibacterial and antifungal concepts into assets through industry partnerships.
  • Prokaryotics Inc.minorStrategic or Co-development Partner · 7 January 2026Collaboration to jointly develop a first-in-class broad-spectrum antifungal for severe invasive infections caused by Candida, Aspergillus, and rare molds. Basilea makes an undisclosed upfront payment and near-term milestones to Prokaryotics, with potential development, regulatory, and commercial milestone payments up to USD 48.5 million plus tiered royalties. Basilea assumes responsibility for clinical development and global commercialization under an exclusive global license.
  • Phare Bio Inc.minorStrategic or Co-development Partner · 11 December 2025Partnership to develop a novel antibiotic using AI-driven molecule design. Combines Basilea's anti-infectives drug development expertise with Phare Bio's AI capabilities for antimicrobial resistance. Phare Bio eligible for success-based payments.
  • Pfizer Inc.coreChannel Partner/ Reseller/ DistributorPfizer is the global license partner for Cresemba (isavuconazole), Basilea's antifungal drug. Pfizer markets Cresemba in over 75 countries. Strong sales performance in Europe triggered a USD 30 million milestone payment to Basilea in November 2025, with global Cresemba sales of USD 652 million for the 12 months ending June 2025.
  • Venatorx PharmaceuticalscoreStrategic or Co-development PartnerBasilea in-licensed the Phase 3-ready antibiotic ceftibuten-ledaborbactam from Venatorx Pharmaceuticals. This in-licensing added a late-stage oral antibiotic candidate targeting complicated urinary tract infections, subsequently supported by BARDA funding of up to USD 147 million.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Basilea Pharmaceutica competitors and assessment

Company assessment

Broad incumbents

  • Pfizer Inc. Pfizer is Basilea's global license partner for Cresemba and the global leader in anti-infectives (including its own antifungal and antibacterial portfolios). Comparable as both a commercial channel for Cresemba and as a broad incumbent whose anti-infective franchise overlaps with Basilea's hospital focus.
  • Melinta Therapeutics: Melinta is a commercial-stage anti-infectives company with a hospital antibiotic portfolio (Baxdela, Vabomere, Orbactiv, Minocin). Comparable as a broader anti-infectives specialty player addressing similar hospital bacterial infection indications as Basilea's Zevtera and ceftibuten-ledaborbactam.

Direct peers

  • F2G (now part of Shionogi): F2G is a direct antifungal peer developing olorofim, a novel mechanism antifungal for invasive fungal infections including resistant Aspergillus. Highly comparable niche competitor pursuing the same immunocompromised-patient hospital antifungal market that Basilea's Cresemba and fosmanogepix target.
  • Scynexis: Scynexis developed and commercialized ibrexafungerp (Brexafemme), a novel glucan synthase inhibitor antifungal. Comparable as a small-cap antifungal innovator focused on invasive fungal infections, with a similar commercial-stage + pipeline profile to Basilea's antifungal franchise.
  • Iterum Therapeutics: Iterum is developing oral sulopenem for complicated urinary tract infections, directly comparable to Basilea's ceftibuten-ledaborbactam. Both are late-stage oral antibiotics targeting drug-resistant cUTIs, a relatively narrow competitive set with similar FDA regulatory pathways.
  • Venatorx Pharmaceuticals: Venatorx originated ceftibuten-ledaborbactam, which Basilea in-licensed. As a private anti-infectives developer focused on beta-lactamase inhibitor combinations and Gram-negative resistance, Venatorx is a direct comparable in the hospital antibacterial space.

Emerging players

  • Cidara Therapeutics: Cidara is developing rezafungin, a next-generation echinocandin antifungal for invasive candidiasis, overlapping with Basilea's Cresemba and fosmanogepix in hospital antifungal treatment of serious fungal infections.
  • Entasis Therapeutics (Innoviva): Entasis, a subsidiary of Innoviva, developed Xacduro for Acinetobacter infections and operates as a focused anti-infectives developer with novel-mechanism antibiotics. Comparable as a niche anti-infectives specialist advancing Gram-negative therapies similar to Basilea's BAL2420 and fosmanogepix programs.
  • Nabriva Therapeutics: Nabriva developed lefamulin (Xenleta), a novel pleuromutilin antibiotic for community-acquired bacterial pneumonia. Comparable as a small-cap anti-infectives company with a marketed hospital antibiotic and a similar commercial-stage + specialty focus.

Others

  • Tetraphase Biosciences: Tetraphase developed eravacycline (Xerava), a novel tetracycline antibiotic for complicated intra-abdominal infections, and was acquired by La Jolla Pharmaceutical. Comparable as a historical reference point for small-cap novel antibiotic developers targeting serious hospital infections, though it no longer operates as an independent entity.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Basilea Pharmaceutica social profiles

Digital presence

Basilea Pharmaceutica compliance and trust

Trust signal

Compliance1 record

Basilea Pharmaceutica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Basilea Pharmaceutica leadership team

Management profile

Number of profiles

Profiles18 records

Basilea Pharmaceutica funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Basilea Pharmaceutica M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Basilea Pharmaceutica

What does Basilea Pharmaceutica do?

Basilea Pharmaceutica is a commercial-stage biopharmaceutical company that develops and commercializes innovative drugs to address severe bacterial and fungal infections. It has two marketed hospital brands — Cresemba (isavuconazole) for invasive fungal infections and Zevtera (ceftobiprole) for bacterial infections — and a clinical pipeline of novel antifungals and antibiotics targeting antimicrobial resistance.

Is Basilea Pharmaceutica a public or private company?

Basilea Pharmaceutica is a public company. It is classified as public and is currently operating.

When was Basilea Pharmaceutica founded?

Basilea Pharmaceutica was founded in 2000. It employs 251 to 500 people.

Where is Basilea Pharmaceutica based?

Basilea Pharmaceutica is headquartered in Allschwil, Switzerland, in the Europe region.

How does Basilea Pharmaceutica make money?

Four revenue lines are on record. Product Royalties (Cresemba) is the primary driver. The others are milestone Payments, product Sales (Zevtera) and non-dilutive Government Funding.

Who are Basilea Pharmaceutica's main competitors?

Broad incumbents on record are Pfizer Inc. and Melinta Therapeutics. Direct peers are F2G (now part of Shionogi), Scynexis, Iterum Therapeutics and Venatorx Pharmaceuticals. Emerging players are Cidara Therapeutics, Entasis Therapeutics (Innoviva) and Nabriva Therapeutics. Tetraphase Biosciences is listed as an others.

Does Basilea Pharmaceutica have an API?

No public API is recorded for Basilea Pharmaceutica.

What industry is Basilea Pharmaceutica in?

Basilea Pharmaceutica's product category is Anti-Infective Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooBasilea Pharmaceutica (SWX:BSLN) Stock Still Looks Undervalued Despite A 101% RunBasilea Pharmaceutica's stock has risen 100.6% over three years, trading at a 17.0x P/E below the biotech sector average of 23.7x. A US$37.5 million milestone payment from Pfizer for Cresemba sales influences earnings durability, but the current valuation remains below a bespoke fair multiple.FinanzNachrichten.deBasilea Pharmaceutica International Ltd, Allschwil: Starke Verkaufszahlen für Cresemba (Isavuconazol) in Europa lösen USD 37.5 Mio. Meilensteinzahlung an Basilea ausBasilea Pharmaceutica announced that strong Cresemba sales in Europe triggered a USD 37.5M milestone payment from Pfizer. The drug's in-market revenue grew 25% to USD 817M in the past year, making it the world's largest antifungal brand.GlobeNewswireStarke Verkaufszahlen für Cresemba® (Isavuconazol) in Europa lösen USD 37.5 Mio. Meilensteinzahlung an Basilea ausBasilea Pharmaceutica announced that Cresemba (isavuconazole) sales by Pfizer in Europe triggered a USD 37.5 million milestone payment. The drug's in-market revenue for July 2025–June 2026 reached USD 817 million, a 25% increase year-over-year, making it the world's largest antimycotic brand.TradingViewBasilea Pharmaceutica Ltd (BSLN) Receives $37.5M Cresemba Milestone PaymentBasilea Pharmaceutica received a $37.5M milestone payment from Pfizer for Cresemba's European sales. Global in-market sales reached $817M in the twelve months to June 2026, up 25% year on year. Further sales-linked milestones or updates on the financial impact would clarify the durability and scale of the contribution.FinanzNachrichten.deBasilea Pharmaceutica International Ltd, Allschwil: Basilea erhöht Finanzprognose für das Gesamtjahr 2026 sowie Finanzziel der «Agenda 2030» und gibt Updates zu den fortgeschrittenen klinischen EntwicBasilea Pharmaceutica raised its 2026 full-year financial guidance, increasing Cresemba and Zevtera-based revenue to CHF 250 million from CHF 210 million, and raised its Agenda 2030 cumulative cashflow target to CHF 650 million from CHF 600 million. The company also updated its late-stage development programs for Ceftibuten-Ledaborbactam and Fosmanogepix, with a combined Phase 2/3 study planned for mid-2027.GlobeNewswireBasilea erhöht Finanzprognose für das Gesamtjahr 2026 sowie Finanzziel der «Agenda 2030» und gibt Updates zu den fortgeschrittenen klinischen EntwicklungsprogrammenBasilea Pharmaceutica raised its 2026 full-year financial forecast, expecting Cresemba and Zevtera revenue of CHF 250 million (up from CHF 210 million) and a cumulative cashflow target of CHF 650 million for its Agenda 2030. The company also updated its late-stage development programs for Ceftibuten-Ledaborbactam and Fosmanogepix, with a combined Phase-2/3 study planned for mid-2027.EuropaWireBasilea outlines IDWeek 2026 data presentations across three anti-infective medicinesBasilea Pharmaceutica announced data presentations for fosmanogepix, isavuconazole, and ceftobiprole at IDWeek 2026 in Washington, D.C., on 21–24 October. Highlights include pediatric expanded-access experience for fosmanogepix and manogepix activity against Candida auris isolates.FinanzNachrichten.deBasilea Pharmaceutica International Ltd, Allschwil: Basilea gibt Präsentation neuer Daten zu Fosmanogepix, Isavuconazol und Ceftobiprol auf der IDWeek 2026 bekanntBasilea Pharmaceutica announced new data on Fosmanogepix, Isavuconazol, and Ceftobiprol at IDWeek 2026 in Washington D.C. The presentations include pediatric data from the Expanded Access Program for Fosmanogepix and activity of manogepix against Candida auris isolates. The company also highlighted US federal funding for its Phase-3 programs.Business & FinancialBasilea Reports Presentation Of New Data For Fosmanogepix, Isavuconazole And Ceftobiprole At Idweek 2026Basilea reported presentations of new data for fosmanogepix, isavuconazole, and ceftobiprole at IDWeek 2026, including expanded access experience, activity against resistant isolates, and pediatric dose selection. The company also highlighted its ceftobiprole phase 3 program funded with approximately $111 million in federal funds.The future of tradingBasilea announces pediatric fosmanogepix data for IDWeek 2026Basilea Pharmaceutica will present pediatric fosmanogepix data at IDWeek 2026, October 21-24 in Washington, D.C. The Phase 3 antifungal presentation covers pediatric expanded-access experience in invasive mold infections and manogepix activity against Candida auris, alongside isavuconazole safety and ceftobiprole dosing.